Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE versus LARYNGOTRACHEAL ANESTHESIA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE versus LARYNGOTRACHEAL ANESTHESIA KIT.
ALPHACAINE HYDROCHLORIDE vs LARYNGOTRACHEAL ANESTHESIA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
None Documented
None Documented
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic